reason report
rais estim reflect strong adopt
bottom line rais sale
estim better reflect strong uptick freestyl libr
ramp sinc launch novemb base iqvia im
reader script trend march libr built instal
base patient new add
recent week addit estim reorder rate base
libr sensor script expect gener sale
libr previous assum
compani grow instal base year-end
assum deceler new patient add level
saw recent two week result sale estim
move higher organ ex
report better reflect strong adopt libr
expect sale y/i oper
ep previous
reiter mp pt believ build sustain
growth momentum acceler growth trajectori certainli
compel believ share fulli valu given
recent multipl expans deliv estim upsid even better
execut behind recent upcom new product launch
believ share could appreci price target appli
current multipl basic unchang ep
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep estim
compani inform leerink partner llc research
revenu mm ep includ stock compens expens exclud amort
pleas refer page import disclosur price chart analyst certif
rx trend deriv im health
rate share market perform price target abbott like
path top-lin growth acceler compani like reinvest
busi absorb acquisit includ alr stj deal
potenti bolster compani sale ep growth outlook becom
formid player med-tech diagnost even broader offer
near term uncertainti around integr stj alr like continu
reflect market sentiment beyond believ margin expans continu
remain key piec abbott long-term invest thesi abbott also attract investor
look safer defens stock healthi dividend yield current
increasingli volatil market help sustain current multipl abbott
succeed drive meaning margin expans nutrit busi margin
mid-teen level post-split still go increas cost effici
suppli chain manufactur abbott pipelin also number smaller
increment new product launch expect next year beyond
pend acquisit xienc stori larg play estim basic
stabl drug elut stent market share next year us abbott like less
acquisit immedi term two larg acquisit underway alreadi estim
reflect uncertainti around integr larg acquisit stj alr
expect share trade assum multipl basic
unchang ep estim assum share sustain current
price-to-earnings multipl ep estim clearli pois sale growth
acceler next year believ current valuat alreadi reflect potenti
execut risk around new product launch -- heavili depend notabl
freestyl libr mri-saf high power devic -- see opportun potenti
risk includ potenti slow end-market growth and/or increas competit
major product includ abbott xienc de total current abbott sale product
recal manufactur warn letter could push oper cost higher hinder sale
growth success pipelin execut key abbott growth stori product
approv time approv becom increasingli uncertain today challeng
regulatori environ success execut margin expans opportun
environ increas price pressur potenti acquisit could dilut
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
